Revive Therapeutics Ltd. (OTCMKTS: RVVTF) has clarified some disclosures in a press release entitled, “Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19.” The press release issued on December 29 offered an update in the company’s US FDA third phase clinical study to evaluate efficacy and safety of Bucillamine. Bucillamine is oral treatment with antiviral and inflammatory properties in mild to moderate COVIF-19 patients.
The enrolment period ended on December 29, 2021
The Study’s enrollment period ended on December 29, 2021, with around 700 individuals participating. In addition, in conjunction with Delta Health, the company has commenced the process of expanding the Study’s patient population in Turkey, which will include study sites from Turkey’s largest hospital group, MLP Care, and Istinye University.
Patient enrolment in Turkey is expected to begin in mid-February, with the Study’s enrollment expected to be completed in Q1-2022. At this time, the company makes no explicit or implicit promises that its product may remove or treat COVID-19 (SARS-2 Coronavirus).
Currently, the company is reviewing Bucillamine for use in the treatment of infectious disorders, with an initial emphasis on acute influenza and COVID-19. In addition, revive is furthering the research of Psilocybin-based therapies in various diseases and disorders by acquiring Psilocin Pharma Corp. Its cannabinoid drug portfolio focuses on uncommon inflammatory disorders, and the company has been given FDA orphan drug status for using Cannabidiol (CBD) to address autoimmune hepatitis and ischemia and reperfusion injury following organ transplantation.
Revive expands Bucillamine study to include omicron
The company expanded the Bucillamine research as a possible Omicron treatment. Bucillamine’s therapeutic potential for the Omicron variant is backed by a recent research study led by the University of California, San Francisco, titled “Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt SARS-CoV-2 spike complex binding to ACE2 in vitro,” which confirmed that powerful thiol drugs, such as Bucillamine, inhibit SARS-CoV-2 infection in vitro, specifically the Delta variant (B.1.617.2) and also minimizes SARS-CoV-2-associated lung injury in vivo and offers robust trials rationale of systemically administered thiol drugs as COVID-19 therapies.
Halo Collective Inc. (OTCMKTS: HCANF) Signs $14 Million Unsecured Loan Agreement With Global Tech Opportunities 6
Post Views: 15 Halo Collective Inc. (OTCMKTS: HCANF) has announced the signing of a Loan Agreement with Global Tech Opportunities...
Mydecine Innovations Group (OTCMKTS: MYCOF) Engages JBN Partners and Attains AI Breakthrough in psychedelics Drug Development
Post Views: 14 Mydecine Innovations Group (OTCMKTS: MYCOF) has announced the engagement of JBN Partners LLC to boost public awareness...
SLANG Worldwide (OTCMKTS: SLGWF) Restructures Sales And Marketing Departments As Part Of Cost Cutting Initiatives
Post Views: 14 SLANG Worldwide (OTCMKTS: SLGWF) has announced that it has done away with the Chief Revenue Officer position...
Revive Therapeutics Ltd. (OTCMKTS: RVVTF) Clarifies Disclosures Regarding The Third Phase Study Of Bucillamine in COVID-19
Post Views: 19 Revive Therapeutics Ltd. (OTCMKTS: RVVTF) has clarified some disclosures in a press release entitled, “Revive Therapeutics Provides...
Snakes & Lattes (OTCMKTS: FUNN) Offers Updates to Shareholders About Name Change, Expansion Plans, And Leadership Changes
Post Views: 3 Snakes & Lattes (OTCMKTS: FUNN) has offered a quarterly update to shareholders and a roadmap on where...
Stereo Vision Entertainment Inc. (OTCMKTS: SVSN) stock Surges After SEC Qualifies Its $500k Reg A
Post Views: 6 Registration Statement. The company had filed a $500k SEC Reg A, which will offer advertising and compliance funding...